Case Report: Discovery a Novel SARS-CoV-2 Variant in a Six-Months Long-Term Swab Positive Female Suffering From Non-Hodgkin Lymphoma.
ORF3a
SARS-CoV-2
long-term infection
non-Hodgkin lymphoma
novel variant
whole genome sequencing
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
05
2021
accepted:
06
07
2021
entrez:
6
8
2021
pubmed:
7
8
2021
medline:
7
8
2021
Statut:
epublish
Résumé
We report the case of a woman with non-Hodgkin lymphoma who remained positive on the molecular assay for SARS-CoV-2 for six months: she has never experienced a severe form of COVID-19 although in absence of seroconversion. The whole SARS-CoV-2 genome analysis was performed by the CleanPlex SARS-CoV-2 Research and Surveillance NGS Panel (PARAGON GENOMICS, Hayward, USA). We found twenty-two mutations in SARS-CoV-2 genome and a novel deleterious ORF3a frameshift c.766_769del corresponding to a unique and novel lineage. The region affected by this frameshift variant is reported as being important in determining SARS-CoV-2 immunogenicity. Patient's immunophenotype showed the absence of B lymphocytes and significantly reduced T-cell count. Only after the treatment with hyperimmune plasma she finally became negative on the swab. Our findings could be helpful in the management of patients with immunodeficiency, particularly when novel variants, potentially altering the virus immune response, are present.
Sections du résumé
BACKGROUND
BACKGROUND
We report the case of a woman with non-Hodgkin lymphoma who remained positive on the molecular assay for SARS-CoV-2 for six months: she has never experienced a severe form of COVID-19 although in absence of seroconversion.
METHODS
METHODS
The whole SARS-CoV-2 genome analysis was performed by the CleanPlex SARS-CoV-2 Research and Surveillance NGS Panel (PARAGON GENOMICS, Hayward, USA).
RESULTS
RESULTS
We found twenty-two mutations in SARS-CoV-2 genome and a novel deleterious ORF3a frameshift c.766_769del corresponding to a unique and novel lineage. The region affected by this frameshift variant is reported as being important in determining SARS-CoV-2 immunogenicity. Patient's immunophenotype showed the absence of B lymphocytes and significantly reduced T-cell count. Only after the treatment with hyperimmune plasma she finally became negative on the swab.
CONCLUSIONS
CONCLUSIONS
Our findings could be helpful in the management of patients with immunodeficiency, particularly when novel variants, potentially altering the virus immune response, are present.
Identifiants
pubmed: 34354952
doi: 10.3389/fonc.2021.705948
pmc: PMC8329552
doi:
Types de publication
Case Reports
Langues
eng
Pagination
705948Informations de copyright
Copyright © 2021 Capoluongo, Nardelli, Esposito, Buonomo, Gelzo, Pinchera, Zappulo, Viceconte, Portella, Setaro, Gentile and Castaldo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Antiviral Res. 2014 Sep;109:97-109
pubmed: 24995382
Int J Biol Macromol. 2021 Feb 15;170:820-826
pubmed: 33359807
BMC Neurol. 2021 May 1;21(1):183
pubmed: 33933026
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
J Mol Biol. 2004 Jul 30;341(1):271-9
pubmed: 15312778
Life Sci. 2020 Nov 15;261:118355
pubmed: 32871183
Genomics. 2020 Sep;112(5):3226-3237
pubmed: 32540495
Cell Mol Immunol. 2020 Aug;17(8):881-883
pubmed: 32555321
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Int J Environ Res Public Health. 2021 Apr 29;18(9):
pubmed: 33947087
Br J Haematol. 2020 Jul;190(2):185-188
pubmed: 32557623
Cell. 2021 May 13;184(10):2605-2617.e18
pubmed: 33831372
Viruses. 2021 Mar 09;13(3):
pubmed: 33803400
Int J Environ Res Public Health. 2021 Feb 08;18(4):
pubmed: 33567746
Biochem Biophys Rep. 2021 Jan 27;26:100933
pubmed: 33527091
Bull World Health Organ. 2020 Jul 1;98(7):495-504
pubmed: 32742035
Virus Evol. 2020 Oct 05;6(2):veaa075
pubmed: 33318859
Epidemiol Infect. 2020 Oct 26;148:e262
pubmed: 33100263
Nat Struct Mol Biol. 2021 Jul;28(7):573-582
pubmed: 34158638
Sci Rep. 2021 Feb 10;11(1):3487
pubmed: 33568759
mSystems. 2020 May 5;5(3):
pubmed: 32371472
Diagnostics (Basel). 2021 Feb 12;11(2):
pubmed: 33673182
Vaccines (Basel). 2021 Mar 11;9(3):
pubmed: 33799505
Genomics. 2020 Sep;112(5):3588-3596
pubmed: 32353474
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508